Critical Outcome Technologies Inc.

Press Release

CRITICAL OUTCOME TECHNOLOGIES AWARDS STOCK OPTIONS

London, Ontario (January 8, 2016): Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT; OTCQB: COTQF), announced today that 147,850 stock options were awarded to a director under the Company's Stock Option Plan. The award was made as a retainer for his service on the Board and its committees in accordance with the directors' compensation program effective October 2015. The options are exercisable at $0.305 with a five year life and vest in equal amounts on January 15, April 15, July 15, and October 15, 2016.

About Critical Outcome Technologies Inc. (COTI)

COTI is a biopharmaceutical company advancing the treatment of cancer through targeted therapeutics. The Company's lead compound, COTI-2, has a novel p53-dependent mechanism of action with selective and potent anti-cancer activity. The initial indication is in gynecologic cancers (ovarian, cervical and endometrial) that will begin patient dosing in a Phase 1 clinical trial at MD Anderson Cancer Center in early 2016. The Company has secured orphan drug status for the ovarian indication in the U.S. and is planning additional studies in other cancer indications such as head & neck, Li-Fraumeni syndrome and AML as well as combination therapies with other leading cancer drugs. Pre-clinical data provides evidence to suggest a potentially dramatic change in the treatment of cancers with mutations of the p53 gene.

Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information, visit www.criticaloutcome.com or contact:

Dr. Wayne Danter
President & CEO
Tel: 519-858-5157
Email: wdanter@criticaloutcome.com

Paul Papi
Vice President Investor Relations
Tel: 508-444-6790 / 519-858-5157
Email: ppapi@criticaloutcome.com